Wells Fargo’s Theriva Biologics TOVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-4
| Closed | -$24 | – | 7082 |
|
|
2024
Q2 | $24 | Sell |
4
-5
| -56% | -$44 | ﹤0.01% | 6475 |
|
|
2024
Q1 | $109 | Hold |
9
| – | – | ﹤0.01% | 6634 |
|
|
2023
Q4 | $99 | Buy |
9
+4
| +80% | +$49 | ﹤0.01% | 6772 |
|
|
2023
Q3 | $67 | Buy |
5
+1
| +25% | +$15 | ﹤0.01% | 6855 |
|
|
2023
Q2 | $109 | Hold |
4
| – | – | ﹤0.01% | 6850 |
|
|
2023
Q1 | $77 | Hold |
4
| – | – | ﹤0.01% | 6994 |
|
|
2022
Q4 | $49 | Hold |
4
| – | – | ﹤0.01% | 7014 |
|
|
2022
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 7375 |
|
|
2022
Q2 | $0 | Buy |
4
+1
| +33% | +$57 | ﹤0.01% | 7496 |
|
|
2022
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 7816 |
|
|
2021
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 7808 |
|
|
2021
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 7524 |
|
|
2021
Q2 | $1K | Hold |
3
| – | – | ﹤0.01% | 6741 |
|
|
2021
Q1 | $1K | Buy |
3
+2
| +200% | +$395 | ﹤0.01% | 6771 |
|
|
2020
Q4 | $0 | Buy |
+1
| New | +$88 | ﹤0.01% | 7020 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 6903 |
|
|
2020
Q2 | – | Sell |
-1
| Closed | -$95 | – | 6826 |
|
|
2020
Q1 | $0 | Buy |
+1
| New | +$114 | ﹤0.01% | 6802 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6742 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6728 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6625 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6453 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6614 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6568 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 6574 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6569 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6526 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6467 |
|
|
2017
Q2 | – | Sell |
-4
| Closed | -$19.9K | – | 6451 |
|
|
2017
Q1 | $23K | Hold |
4
| – | – | ﹤0.01% | 5682 |
|
|
2016
Q4 | $27K | Hold |
4
| – | – | ﹤0.01% | 5551 |
|
|
2016
Q3 | $62K | Buy |
+4
| New | +$59.9K | ﹤0.01% | 5188 |
|
|
2016
Q2 | – | Sell |
-1
| Closed | -$18.8K | – | 6326 |
|
|
2016
Q1 | $16K | Sell |
1
-6
| -86% | -$90.2K | ﹤0.01% | 5571 |
|
|
2015
Q4 | $145K | Buy |
7
+6
| +600% | +$127K | ﹤0.01% | 4666 |
|
|
2015
Q3 | $25K | Buy |
+1
| New | +$24.6K | ﹤0.01% | 5476 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 5847 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 5778 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6110 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6003 |
|
|
2014
Q2 | – | Sell |
-3
| Closed | -$64K | – | 6283 |
|
|
2014
Q1 | $64K | Buy |
+3
| New | +$62.1K | ﹤0.01% | 4847 |
|
|
2013
Q3 | – | Sell |
-3
| Closed | -$48K | – | 5845 |
|
|
2013
Q2 | $48K | Buy |
+3
| New | +$41K | ﹤0.01% | 4631 |
|
Other funds holding TOVX
HCM
AFM
AC
MP
HF
TSS
Wells Fargo's TOVX Position: Q3 2024 in Review
Wells Fargo sold out of Theriva Biologics (TOVX) in Q3 2024, closing a stake of 4 shares — an estimated $24 sold.
Wells Fargo first reported a position in TOVX in Q2 2013 and held it in 24 quarters. The position peaked at $145K in Q4 2015. 18 funds tracked by Wall St. Rank hold TOVX as of Q3 2024.
- Wells Fargo reported no remaining Theriva Biologics position as of Q3 2024 after selling out during the quarter.
- Wells Fargo sold 4 Theriva Biologics shares in Q3 2024, an estimated $24.
- Wells Fargo first reported a position in Theriva Biologics in Q2 2013 and held it in 24 quarters.
- Wells Fargo's Theriva Biologics position peaked at $145K in Q4 2015.
- 18 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2024.
Based on Wells Fargo's 13F filing for Q3 2024, filed 13 Nov 2024.